Impact of smoking on the effectiveness of different non-small-cell lung cancer therapies
- PMID: 40792148
- PMCID: PMC12335674
- DOI: 10.21037/tcr-2025-145
Impact of smoking on the effectiveness of different non-small-cell lung cancer therapies
Abstract
Background and objective: Smoking reshapes tumor genetics, host immunity, and drug metabolism in non-small-cell lung cancer (NSCLC), yet its therapy-specific impact is often overlooked. This review sought to clarify how current, former, and never smokers respond to each major NSCLC modality and to outline opportunities for treatment optimization.
Methods: A systematic search of PubMed, Web of Science, and Google Scholar up to April 2025 identified 146 high-quality trials, cohorts, and meta-analyses that reported outcomes by smoking status. Hazard ratios, response rates, and complication data, and random-effects meta-analyses were performed.
Key content and findings: Immune-checkpoint inhibitors improved overall survival across all smoking groups (pooled HR_OS =0.74), although active smokers exhibited shorter response durability because of faster drug clearance and persistent immune dysfunction despite higher tumor-mutational burden and programmed death-ligand 1 (PD-L1) expression. Never-smokers achieved markedly better progression-free survival with EGFR tyrosine-kinase inhibitors [hazard ratio (HR) 0.32 vs. 0.54 in smokers], whereas ALK inhibitors showed little disparity. Smoking attenuated chemotherapy and radiotherapy benefits through cytochrome-P450 induction, tumor hypoxia, and enhanced DNA repair, and it increased postoperative pulmonary-complication rates two- to five-fold after lung resection; cessation ≥8 weeks reduced but did not eliminate this surgical risk.
Conclusions: Smoking status is a potent, modifiable determinant of NSCLC outcomes. Embedding structured cessation programs, tailoring dose or schedule, and incorporating smoking-informed molecular profiling into routine care could heighten efficacy and reduce toxicity. Future trials should stratify participants by detailed tobacco history to advance truly personalized, behavior-integrated oncology.
Keywords: Chemotherapy; lung cancer; radiotherapy; smoking; surgery.
Copyright © 2025 AME Publishing Company. All rights reserved.
Conflict of interest statement
Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-145/coif). The author has no conflicts of interest to declare.
References
-
- Sarcar SN. Lung Cancer Therapeutics Landscape, A Current Overview. Cell Cellular Life Sci J 2022. Available online: 10.23880/cclsj-16000169. - DOI
-
- Czyżykowski R, Połowinczak-Przybyłek J, Potemski P. Nicotine-induced resistance of non-small cell lung cancer to treatment--possible mechanisms. Postepy Hig Med Dosw (Online 2016;70:186-93. - PubMed
-
- Abdullah MY, Alsaleh EH, Alkhulaiwi NA, et al. A review on strategies for smoking cessation and the management of nicotine dependence. Int J Community Med Public Health 2024;11:4107-12.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous